Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

Inclusion Criteria:

* Histologically confirmed invasive breast cancer with stage IV disease, according to AJCC 6th edition (American Joint Committee on Cancer), either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological study
* All tumors must be ER-, PGR- and HER2-negative
* 18 years of age or older
* Paraffin tissue block is required from the primary tumor tissue or from diagnostic metastatic biopsy at time of relapse
* Measurable disease by RECIST
* Performance status of 0,1 or 2 by ECOG criteria (Eastern Cooperative Oncology Group)
* Life expectancy greater than 12 weeks
* Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol

Exclusion Criteria:

* More than 1 prior chemotherapy for the treatment of recurrent or metastatic breast cancer
* Prior treatment with cisplatin, carboplatin, or other platinum chemotherapy agents
* Active brain metastases or unevaluated neurological symptoms suggestive of brain metastases
* Intercurrent illness or other major medical condition or comorbid condition that might affect study participation
* Significant history of uncontrolled cardiac disease such as uncontrolled hypertension, unstable angina, recent myocardial infarction, uncontrolled congestive heart failure, cardiomyopathy either symptomatic or asymptomatic but with decreased ejection fraction \<45%
* Renal dysfunction for which cisplatin dose would either require dose modification or would be considered unsafe
* Pregnant or nursing women
* History or other malignancy that was not treated with curative intent